Monday, Pharmaceutical Product Development, Inc. (PPDI) reported a steep decline in profit for the fourth quarter from a year ago on lower revenue and higher expenses, including R&D costs.
PPD sold its subsidiaries - Piedmont Research Center, LLC and PPD Biomarker Discovery Sciences, LLC, this fiscal.
Excluding income from discontinued operations, PPD's profit from continuing operations decreased to $17.63 million or $0.16 per share from $47.12 million or $0.40 per share in the year-ago period. On an average, 11 analysts polled by Thomson Reuters expected earnings of $0.23 per share. Analysts' estimates typically exclude one-time items.
This year's results include impairments of an intangible asset and equity investments totaling $10.0 million, net of tax, related to the company's dermatology program within the compound partnering business and the company's investment portfolio, respectively.
Fourth-quarter net revenue decreased to $357.4 million from $363.1 million. However, the quarter's revenue was above analysts expectations of $314.33 million. Income from operations fell to $23.9 million from $71.7 million
PPD's development segment net revenue decreased to $328.1 million from $338.7 million, while discovery sciences segment net revenue increased to $0.5 million from $0.1 million.
The company's total direct costs increased to $185.95 million from $179.51 million, R&D costs rose to $13.34 million from $1.04 million and S,G&A expenses shot up to $107.03 million from $95.95 million in the year-ago period.
New business authorizations for the fourth quarter totaled $465.6 million with backlog at December 31, 2009, standing at $3.0 billion. Contract cancellations and adjustments for the quarter were $284.9 million, including three large project cancellations that together represented approximately four percent of year-end backlog.
For the full-year, PPD's profit declined to $140.13 million or $1.34 per share from $187.94 million or $1.56 per share last year. Revenue decreased to $1.42 billion from $1.55 billion. Analysts expected full-year EPS of $1.26 on revenue of $1.30 billion.
PPDI closed Monday's regular trading session at $22.13, down $0.37 or 1.64%, on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.